unknown
Stage
About
Aggamin is a biotechnology company developing an extracorporeal device to treat preeclampsia by reducing circulating pathogenic proteins, aiming to improve maternal and neonatal outcomes.
Explore Aggamin's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.